Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform
February 22, 2018 at 07:18 AM EST
Feb 22 (Reuters) - Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.
